Our study underscores the potential of targeting meiotic recombination proteins, like SYCP2, and the unexplored function of ABL1 at R-loops, as novel therapeutic strategies in overcoming drug resistance and improving outcomes for patients with ovarian cancer. This evidence concerns the gene ABL1 and ovarian carcinoma.